Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Most prostate cancer activists (and certainly those on the West Coast) will want to be aware of an “OpEd” into today’s issue of the San Francisco Chronicle. The OpEd says it is by Laura Esserman, MD, but the credits suggest that actually it is by Dr. Esserman in conjunction with Ian Thompson, MD, the co-authors [...]
Filed under: Diagnosis, Risk | 4 Comments »
This weekend’s news report includes items on: Numbers of biopsy cores and accuracy of diagnosis for focal therapy Early data from the Prostate Cancer Research International: Active Surveillance (PRIAS) study Ultrasensitive PSA testing and risk of progression following radical prostatectomy
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surviellance, biopsy, cores, focal therapy, progression, PSA, radical prostatectomy, ultrasensitive | Leave a Comment »
The evidence supporting a role for the combination of dutasteride with ketoconazole as a form of second- or third-line hormone therapy for patients with castration-resistant prostate cancer (CRPC) appears to be increasing.
Filed under: Management, Treatment, Uncategorized | Tagged: castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole | 1 Comment »
Data presented last Monday at the annual meeting of the American Society for Radiation Oncology (ASTRO) suggest a possible role of anticoagulant therapy (using drugs like aspirin, warfarin, or clopidogrel/Plavix) in combination with radiation for the treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: anticoagulant, aspirin, clopidogrel, radiation, warfarin | Leave a Comment »
In today’s news reports from sources other than the ASTRO meeting, we note items dealing with: PSA bounce in brachytherapy patients Fatal prostate cancer and a history of smoking Ketoconazole + dutasteride in treatment of CRPC
Filed under: Management, Prevention, Risk, Treatment | Tagged: Avodart, brachytherapy, castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole, PSA bounce, smoking | 1 Comment »
Other news reports today — from sources not related to the ASTRO annual meeting — address such topics as: Perceptions about the US Preventive Services Task Force recommendations regarding the use of PSA testing men men > 75 years Renal insufficiency in men of long-term drug therapy for prostate cancer Cetuximab + doxirubicin in the [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: cetruximab, doxirubicin, estrogen, PSA testing, renal in sufficiency, USPSTF | Leave a Comment »
Two new studies reported at the American Society for Radiation Oncology (ASTRO) annual meeting yesterday discuss the potential of shorter courses of “hypofractionated” radiation therapy in the treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: hypofractionated, outcome, radiation, risk | 1 Comment »
Based on retrospective analysis of 2,132 prostate cancer patients in their single-institution database, researchers from the Fox Chase Cancer Center have reported that patients receiving radiation as first-line treatment for localized prostate cancer and who have a rising PSA within 18 months are at a significantly increased risk of death from prostate cancer compared to [...]
Filed under: Management, Treatment | Tagged: biochemical failure, PSA, radiation | Leave a Comment »
“Evidence continues to mount that the use of statins is inversely correlated with the risk of [high grade] prostate cancer,” says Elizabeth Platz, co-director of the cancer prevention and control program at the Johns Hopkins Kimmel Cancer Center, who is quoted in a report on the HealthDay web site.
Filed under: Diagnosis, Prevention, Risk | Tagged: Prevention, risk, statins | Leave a Comment »
Two papers presented at the annual meeting of the American Society for Radiation Oncology (ASTRO) offer some further information on the application of proton beam radiation therapy (PBRT) in treatment of prostate cancer.
Filed under: Management, Treatment | Tagged: PBRT, proton beam radiation therapy | Leave a Comment »
The use of radiation to treat cancer is highly dependent on a detailed appreciation of the physics that underlies the medical application of radioactivity. A new set of guidelines from the American Association for Physicists in Medicine (AAPM) provides technical guidance on prostate brachytherapy procedures
Filed under: Management, Treatment, Uncategorized | Tagged: brachytherapy, guideline, standardization | Leave a Comment »
A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed [...]
Filed under: Management, Treatment | Tagged: first line, hormone therapy, localized, radiation, RTOG 94-08 | Leave a Comment »
In August this year, Vis and Schröder published the first of two summary reviews on the key targets of hormonal treatment of prostate cancer. The second of these two key reviews has now appeared in the November issue of BJU International.
Filed under: Management, Treatment, Uncategorized | Tagged: 5-ARIs, 5α-reductase inhibitor | 11 Comments »
Earlier this year, Dendreon stated that the company expected to file a revised Biologics License Application (BLA) for sipuleucel-T (Provenge) by mid-November. The company reported today that filing of the revised BLA is now complete.
Filed under: Drugs in development, Uncategorized | Tagged: Provenge, sipuleucel-T | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site